Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Pseudomonas aeruginosa.
Connection Strength

1.736
  1. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment. Int J Antimicrob Agents. 2015 Sep; 46(3):313-8.
    View in: PubMed
    Score: 0.335
  2. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J Antimicrob Chemother. 2013 Apr; 68(4):881-7.
    View in: PubMed
    Score: 0.279
  3. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother. 2012 Mar; 56(3):1223-8.
    View in: PubMed
    Score: 0.262
  4. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Int J Antimicrob Agents. 2004 Aug; 24(2):173-7.
    View in: PubMed
    Score: 0.157
  5. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother. 1998 Mar; 42(3):659-65.
    View in: PubMed
    Score: 0.100
  6. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. J Antimicrob Chemother. 2016 Mar; 71(3):678-84.
    View in: PubMed
    Score: 0.086
  7. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis. 1991 Sep; 164(3):499-506.
    View in: PubMed
    Score: 0.064
  8. Single daily dosing of amikacin in an in-vitro model. J Antimicrob Chemother. 1991 May; 27 Suppl C:15-9.
    View in: PubMed
    Score: 0.063
  9. Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model. J Antimicrob Chemother. 1986 Nov; 18 Suppl D:49-54.
    View in: PubMed
    Score: 0.046
  10. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother. 1986 May; 29(5):927-9.
    View in: PubMed
    Score: 0.044
  11. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. J Antimicrob Chemother. 1986 Mar; 17 Suppl A:1-5.
    View in: PubMed
    Score: 0.044
  12. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1985 Jul; 28(1):64-8.
    View in: PubMed
    Score: 0.042
  13. Use of an in-vitro kinetic model to study antibiotic combinations. J Antimicrob Chemother. 1985 Jan; 15 Suppl A:221-6.
    View in: PubMed
    Score: 0.040
  14. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Jul; 20(1):44-9.
    View in: PubMed
    Score: 0.034
  15. Synergistic activity of trimethoprim and amikacin against gram-negative bacilli. Antimicrob Agents Chemother. 1977 Sep; 12(3):349-52.
    View in: PubMed
    Score: 0.024
  16. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically? J Chemother. 2017 Dec; 29(6):351-357.
    View in: PubMed
    Score: 0.024
  17. Effect of clindamycin on the in vitro activity of amikacin and gentamicin against gram-negative bacilli. Antimicrob Agents Chemother. 1976 Apr; 9(4):661-4.
    View in: PubMed
    Score: 0.022
  18. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. J Antimicrob Chemother. 1990 Jun; 25(6):941-8.
    View in: PubMed
    Score: 0.015
  19. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul; 31(7):1054-60.
    View in: PubMed
    Score: 0.012
  20. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother. 1985 Mar; 27(3):343-9.
    View in: PubMed
    Score: 0.010
  21. An artificial capillary in vitro kinetic model of antibiotic bactericidal activity. J Infect Dis. 1981 Dec; 144(6):583-7.
    View in: PubMed
    Score: 0.008
  22. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct; 20(4):463-9.
    View in: PubMed
    Score: 0.008
  23. Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct; 20(4):539-41.
    View in: PubMed
    Score: 0.008
  24. Gram-negative rod bacteremia in cancer patients. A review with emphasis on the antibody response. Eur J Cancer. 1975 Aug; 11suppl:39-47.
    View in: PubMed
    Score: 0.005
  25. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994 Oct; 38(10):2351-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.